Maze Therapeutics’ (MAZE) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Maze Therapeutics (NASDAQ:MAZE) in a research report released on Thursday morning,Benzinga reports. They currently have a $110.00 target price on the stock.

Several other equities research analysts also recently issued reports on the company. BTIG Research reissued a “buy” rating and issued a $46.00 price objective on shares of Maze Therapeutics in a research note on Tuesday, September 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Monday, September 21st. Citigroup assumed coverage on Maze Therapeutics in a report on Wednesday. They issued a “buy” rating and a $50.00 target price on the stock. Wedbush reissued an “outperform” rating and issued a $48.00 price target on shares of Maze Therapeutics in a research report on Wednesday. Finally, TD Cowen upgraded shares of Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Three analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $63.40.

Maze Therapeutics Trading Down 0.6%

NASDAQ MAZE opened at $26.05 on Thursday. Maze Therapeutics has a twelve month low of $21.95 and a twelve month high of $53.65. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. The stock has a market cap of $1.45 billion, a price-to-earnings ratio of -10.34 and a beta of 2.17. The firm’s 50 day moving average price is $27.12 and its two-hundred day moving average price is $29.02.

Maze Therapeutics (NASDAQ:MAZE) last released its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.76). Equities analysts anticipate that Maze Therapeutics will post -2.72 EPS for the current year.

Insider Transactions at Maze Therapeutics

In related news, CEO Jason Coloma sold 11,411 shares of the business’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $26.01, for a total value of $296,800.11. Following the completion of the sale, the chief executive officer owned 27,362 shares of the company’s stock, valued at approximately $711,685.62. The trade was a 29.43% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CMO Harold Bernstein sold 9,705 shares of the stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $26.22, for a total value of $254,465.10. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 191,459 shares of company stock valued at $5,263,539 over the last 90 days. Company insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of MAZE. Frazier Life Sciences Management L.P. lifted its stake in shares of Maze Therapeutics by 10.2% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock valued at $150,182,000 after purchasing an additional 465,641 shares during the last quarter. TRV GP IV LLC acquired a new position in Maze Therapeutics during the second quarter worth $133,502,907. ARCH Venture Management LLC bought a new position in Maze Therapeutics during the second quarter valued at about $122,983,582. BlackRock Inc. bought a new position in Maze Therapeutics during the second quarter valued at about $104,525,000. Finally, Jupiter Topco LLC acquired a new stake in shares of Maze Therapeutics in the second quarter worth about $101,764,000.

Key Stories Impacting Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Citigroup issued bullish coverage. A correction clarified that Citi initiated Maze Therapeutics with a “Buy” rating and a $50 price target, implying substantial upside from recent levels. Citi subsequently upgraded the stock to “Strong Buy.” Correction: Citigroup Initiates Maze Therapeutics at Buy With $50 Price Target
• Positive Sentiment: Additional analysts also see significant upside. BTIG initiated coverage with a “Buy” rating and a $50 target, while HC Wainwright reaffirmed its “Buy” rating and maintained a $110 target—more than four times the recent share price. BTIG Initiates Maze Therapeutics at Buy With $50 Price Target HC Wainwright Reaffirms Buy Rating
• Positive Sentiment: Wedbush rated the company “Outperform.” The additional constructive view reinforces the broader analyst optimism surrounding Maze’s prospects. Maze Therapeutics Earns Outperform Rating from Wedbush
• Neutral Sentiment: Reported short interest was zero shares. The September 24 report listed no shares sold short and a 0.0-day short-interest ratio. This could reduce evidence of bearish positioning, although the figure may reflect a reporting or data issue given the accompanying reference to a large increase in short interest. Maze Therapeutics Shares Moved, So What Is Driving Attention Now?

Maze Therapeutics Company Profile

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze’s lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.